Description
A new child-friendly formulation of artemether/lumefantrine aims to improve malaria treatment in vulnerable pediatric populations. Infants and children under five suffer the highest burden of malaria, yet child-specific formulations were lacking until recently. A palatable, easy-to-administer version of artemether/lumefantrine (AL), the WHO-recommended treatment for uncomplicated Plasmodium falciparum malaria. Clinical trials in 899 African children showed cure rates over 96%, matching the efficacy of crushed AL tablets while improving taste and ease of use. This innovation supports better adherence and treatment outcomes, helping to preserve the effectiveness of artemisinin-based combination therapies.